Astec Lifesciences Limited (IN:ASTEC)
:ASTEC
Want to see IN:ASTEC full AI Analyst Report?
ASTEC Stock Chart & Stats
₹703.50
-₹43.60(-3.76%)
At close: 4:00 PM EST
₹703.50
-₹43.60(-3.76%)
Day’s Range― - ―
52-Week Range₹512.35 - ₹990.88
Previous CloseN/A
Volume22.45K
Average Volume (3M)412.49K
Market Cap
₹17.14B
Enterprise Value₹21.55B
Total Cash (Recent Filing)₹96.91M
Total Debt (Recent Filing)₹3.67B
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-56.86
Shares Outstanding22,282,238
10 Day Avg. Volume47,730
30 Day Avg. Volume412,490
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)2.96
Price to Sales (P/S)2.58
P/FCF Ratio-9.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.6
Revenue Forecast (FY)₹6.66B
Bulls Say, Bears Say
Bulls Say
Diversified Product MixAstec's integrated product set (technical actives, chemical intermediates, and finished formulations) provides durable resilience: it supports margin capture across the value chain, reduces exposure to a single product cycle, and enables cross‑selling to domestic and export customers, strengthening long‑term revenue stability.
Revenue ReboundThe FY26 top‑line recovery indicates the company can regain volumes and realizations after prior declines. Sustained revenue growth is a prerequisite for restoring profitability and leveraging fixed manufacturing assets; if maintained, it supports operating leverage and improves the path to positive cash generation over months to quarters.
Substantial Asset/equity BaseA meaningful asset and equity base provides durable operational capacity and collateral for financing, allowing the company to maintain production, pursue incremental capex or retrofits, and absorb cyclical shocks. This underpins recovery potential and supports continuity of export and domestic supply contracts.
Bears Say
Sustained LossesMulti‑year losses materially weaken internal capital formation and return metrics. Persistent negative profitability erodes retained earnings, limits management's ability to invest in higher‑value actives or efficiency projects, and increases reliance on external funding—constraining strategic options over the medium term.
Weak Cash GenerationChronic free cash flow deficits create structural funding risk: the business cannot self‑fund working capital or capex needs, increasing dependence on debt or equity raises. This undermines sustainable reinvestment, exposes the company to refinancing risk, and can force suboptimal asset sales or cutbacks.
Rising LeverageHigher leverage amplifies solvency and interest‑coverage risk if earnings stay weak. Elevated debt limits financial flexibility, increases fixed financing costs that depress margins, and reduces capacity to invest in upgrading facilities or R&D—heightening vulnerability to industry shocks or rising rates.
Astec Lifesciences Limited News
ASTEC FAQ
What was Astec Lifesciences Limited’s price range in the past 12 months?
Astec Lifesciences Limited lowest stock price was ₹512.35 and its highest was ₹990.88 in the past 12 months.
What is Astec Lifesciences Limited’s market cap?
Astec Lifesciences Limited’s market cap is ₹17.14B.
When is Astec Lifesciences Limited’s upcoming earnings report date?
Astec Lifesciences Limited’s upcoming earnings report date is Jul 29, 2026 which is in 45 days.
How were Astec Lifesciences Limited’s earnings last quarter?
Astec Lifesciences Limited released its earnings results on Apr 27, 2026. The company reported -₹3.5 earnings per share for the quarter, missing the consensus estimate of ₹0.5 by -₹4.
Is Astec Lifesciences Limited overvalued?
According to Wall Street analysts Astec Lifesciences Limited’s price is currently Overvalued.
Does Astec Lifesciences Limited pay dividends?
Astec Lifesciences Limited pays a Annually dividend of ₹1.5 which represents an annual dividend yield of N/A. See more information on Astec Lifesciences Limited dividends here
What is Astec Lifesciences Limited’s EPS estimate?
Astec Lifesciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Astec Lifesciences Limited have?
Astec Lifesciences Limited has 22,282,238 shares outstanding.
What happened to Astec Lifesciences Limited’s price movement after its last earnings report?
Astec Lifesciences Limited reported an EPS of -₹3.5 in its last earnings report, missing expectations of ₹0.5. Following the earnings report the stock price went up 3.668%.
Which hedge fund is a major shareholder of Astec Lifesciences Limited?
Currently, no hedge funds are holding shares in IN:ASTEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Astec Lifesciences Limited
Astec LifeSciences Limited, operating with its subsidiaries, is actively engaged in the manufacturing, distribution, and sale of essential active ingredients for agrochemicals and crucial intermediates for the pharmaceutical sector within the Indian market. The company boasts a comprehensive product portfolio that includes a diverse range of agricultural chemicals, such as various fungicides, insecticides, and herbicides. Furthermore, Astec LifeSciences specializes in producing an extensive and complex assortment of chemical intermediates. These encompass a broad spectrum of compounds, including various halides and silane derivatives; fluorinated aromatic, aliphatic, and heterocyclic intermediates; as well as pyridine derivatives, carboxylic acids, benzyl alcohols, ketones, benzophenones, and different mercaptans. Its specialized offerings also extend to intricate chemical structures like thiopyrimidines, sulfonyl chlorides, sulphonamides, carbamates, pyrimidine diones, pyrazolones, morpholine derivatives, triazines, ethers, epoxides, and a host of other aliphatic and aromatic derivatives, such as brominated compounds, cyanides, esters, carboxamides, amines, and alcohols. Beyond its domestic operations, the company also engages in the export of its chemical products. Established in 1994, Astec LifeSciences is headquartered in Mumbai, India, and operates as a subsidiary of Godrej Agrovet Limited.
Technical Analysis
Heranba Industries Limited
―
IG Petrochemicals Ltd.
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Punjab Chemicals & Crop Protection Ltd.
―
Uniphos Enterprises Limited
―